Rezolute: The bet on Rare Diseases: How the Company Plans to Conquer the Market with its Orphan Drug Candidate RZ358

Rezolute is a biopharmaceutical company developing therapies for rare and metabolic diseases. The focus is on the development of treatments for hyperinsulinism, a rare genetic disorder that can lead to dangerously low blood sugar levels. The leading drug candidate is Ersodetug. RZ358 is currently in the pivotal Phase 3 trial ("sunRIZE”), with results expected in December 2025. Rezolute (NASDAQ: RZLT) is a forward-looking biopharmaceutical company in the clinical phase, with a strategy focused on developing groundbreaking therapies...